Viatris Other Income (Expense) decreased by 54.7% to -$47.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.2%, from -$99.30M to -$47.50M. Over 3 years (FY 2021 to FY 2025), Other Income (Expense) shows a downward trend with a 350.6% CAGR.
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
other_income_expense_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$4.20M | -$5.80M | $21.90M | -$33.70M | -$13.50M | $20.60M | $1.82B | $69.90M | $107.50M | $92.00M | $139.10M | -$6.10M | $10.20M | -$226.50M | -$99.30M | -$333.50M | -$67.10M | -$30.70M | -$47.50M |
| QoQ Change | — | -38.1% | +477.6% | -253.9% | +59.9% | +252.6% | >999% | -96.2% | +53.8% | -14.4% | +51.2% | -104.4% | +267.2% | <-999% | +56.2% | -235.9% | +79.9% | +54.2% | -54.7% |
| YoY Change | — | — | — | — | -221.4% | +455.2% | >999% | +307.4% | +896.3% | +346.6% | +99.0% | -105.7% | -88.9% | — | -171.4% | <-999% | -757.8% | +86.4% | +52.2% |
| Segment | FY'21 | FY'22 | FY'23 |
|---|---|---|---|
| Other Foreign Operations | -$0.04 | $0.02 | $0.20 |
| Total | $5.80M | $1.79B | — |
All segment values are derived from annual filings.
Other Foreign Operations was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.